BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,360,112 | -36.3% | 36,039 | -23.1% | 0.05% | -25.0% |
| Q2 2023 | $2,134,987 | +55.0% | 46,861 | +38.0% | 0.07% | +54.5% |
| Q1 2023 | $1,377,377 | -11.4% | 33,959 | +11.4% | 0.04% | -13.7% |
| Q4 2022 | $1,553,871 | +23.9% | 30,486 | +30.9% | 0.05% | +18.6% |
| Q3 2022 | $1,254,000 | -36.7% | 23,286 | -24.5% | 0.04% | -29.5% |
| Q2 2022 | $1,980,000 | -17.2% | 30,826 | 0.0% | 0.06% | +32.6% |
| Q1 2022 | $2,390,000 | -9.7% | 30,826 | 0.0% | 0.05% | -9.8% |
| Q4 2021 | $2,646,000 | +6.7% | 30,826 | 0.0% | 0.05% | 0.0% |
| Q3 2021 | $2,479,000 | +33.1% | 30,826 | +33.3% | 0.05% | +37.8% |
| Q2 2021 | $1,862,000 | +0.7% | 23,126 | +5.5% | 0.04% | +19.4% |
| Q1 2021 | $1,849,000 | +44.7% | 21,926 | +37.7% | 0.03% | +3.3% |
| Q4 2020 | $1,278,000 | -0.2% | 15,926 | 0.0% | 0.03% | -11.8% |
| Q3 2020 | $1,281,000 | -6.6% | 15,926 | 0.0% | 0.03% | -2.9% |
| Q2 2020 | $1,371,000 | -0.2% | 15,926 | -5.9% | 0.04% | -14.6% |
| Q1 2020 | $1,374,000 | -2.9% | 16,926 | 0.0% | 0.04% | +41.4% |
| Q4 2019 | $1,415,000 | -0.3% | 16,926 | +4.3% | 0.03% | +3.6% |
| Q3 2019 | $1,419,000 | +4.2% | 16,226 | -2.4% | 0.03% | +3.7% |
| Q2 2019 | $1,362,000 | +1.3% | 16,626 | +0.6% | 0.03% | +8.0% |
| Q1 2019 | $1,344,000 | +59.4% | 16,526 | +29.0% | 0.02% | +38.9% |
| Q4 2018 | $843,000 | -35.3% | 12,811 | -24.2% | 0.02% | -18.2% |
| Q3 2018 | $1,303,000 | +9.6% | 16,899 | +5.0% | 0.02% | +10.0% |
| Q2 2018 | $1,189,000 | +22.6% | 16,097 | +7.9% | 0.02% | +17.6% |
| Q1 2018 | $970,000 | -14.2% | 14,914 | -14.8% | 0.02% | 0.0% |
| Q4 2017 | $1,131,000 | +24.1% | 17,502 | +20.6% | 0.02% | +30.8% |
| Q3 2017 | $911,000 | +9.8% | 14,510 | +5.8% | 0.01% | 0.0% |
| Q2 2017 | $830,000 | +3.5% | 13,714 | -11.3% | 0.01% | +8.3% |
| Q1 2017 | $802,000 | +23.6% | 15,457 | +5.7% | 0.01% | +20.0% |
| Q4 2016 | $649,000 | +27.3% | 14,630 | +36.5% | 0.01% | +25.0% |
| Q3 2016 | $510,000 | +44.9% | 10,717 | +37.8% | 0.01% | +33.3% |
| Q2 2016 | $352,000 | +58.6% | 7,776 | +150.9% | 0.01% | +100.0% |
| Q3 2014 | $222,000 | -41.7% | 3,099 | -40.2% | 0.00% | -50.0% |
| Q1 2014 | $381,000 | -88.9% | 5,179 | -90.1% | 0.01% | -89.3% |
| Q3 2013 | $3,430,000 | – | 52,210 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |